Booth Bruce 4

What Happened

• Bruce Booth, a director of Kymera Therapeutics (KYMR), reported multiple open-market sales totaling 513,245 shares for aggregate proceeds of approximately $56.46 million. The sales occurred on June 26 and June 29, 2026, at prices reported (weighted averages and individual trades) roughly between $105.02 and $119.04 per share.
• These transactions are reported as sales (code S). Many of the shares sold were held by Atlas Venture–affiliated vehicles (see footnotes) and at least some sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.

Key Details

• Transaction dates: June 26, 2026 and June 29, 2026. Prices per trade ranged (weighted averages reported) roughly $105.02–$119.04; total proceeds ≈ $56.46M for 513,245 shares.
• Ownership after the transactions: not specified in the excerpt provided — check the full Form 4 filing(s) for post-transaction holdings. Several lines disclose the shares are held directly by Atlas Venture funds and the reporting person disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest (see footnote F15/F3).
• Notable footnotes: F1 indicates a Rule 10b5-1 plan adopted by Atlas Venture funds on 12/11/2025; multiple footnotes note weighted-average prices and price ranges across multiple trades (see filing). The report is split across two filings due to the 30-line Table I limitation; this is the first of two.
• Timeliness: Form 4 was filed on June 30, 2026. Given the trade dates (June 26 and June 29), this filing appears to have been made within the standard two-business-day reporting window.

Context

• These are sales (often routine for funds or prearranged plans) rather than purchases; sales do not necessarily indicate management view on company fundamentals. Because many shares were held and sold by Atlas Venture funds (institutional vehicles) and Booth disclaims beneficial ownership of those fund holdings (except for any pecuniary interest), these trades reflect affiliated fund activity as well as the reporting person’s role in those entities.
• Several reported prices are weighted averages covering multiple executions; consult the full Form 4 and footnotes for detailed per-trade price breakdowns and to confirm exact holdings after the sales.